AOCI at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's AOCI?
- Enliven Therapeutics (ELVN) reported AOCI of -$382K in Q1 2026.
- How has Enliven Therapeutics's AOCI changed year-over-year?
- Enliven Therapeutics's AOCI decreased by 2287.5% year-over-year, from -$16K to -$382K.
- What is the long-term trend for Enliven Therapeutics's AOCI?
- Over 5 years (2020 to 2025), Enliven Therapeutics's AOCI has grown at a 142.3% compound annual growth rate (CAGR), from $4K to $334K.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.